TherapeuticsMD, Inc. (TXMD)

From the record

TherapeuticsMD, Inc.'s filings since 2017 show 11 warning events of 4 kinds: a debt default or acceleration notice (8-K item 2.04, 3 times, the latest 2022-04-20); a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2023-01-12); an auditor change (8-K item 4.01, 2 times, the latest 2026-01-21); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2026-04-01) (its current reports).

From the record

TherapeuticsMD, Inc.'s 7 filed years say what it did: revenue went from $50 million in fiscal 2019 to $3 million in fiscal 2025, down 37.3% a year; it rose in 4 of 6 years; the deepest fall was 98% from fiscal 2022 to fiscal 2023; net income was positive in 1 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, TherapeuticsMD, Inc. lost about 2 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 0.3% over the year (the filed statements).

From the record

TherapeuticsMD, Inc.'s standing among 315 graded names in its industry family: revenue of $3 million in fiscal 2025 ranks in the bottom 31% by size; a net margin of -18.8% ranks in the top 32%; revenue growth of -64.9% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).

From the record

TherapeuticsMD, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Walker, Marlan D (Chief Executive Officer, as filed), filing under that title since 2023-02-13, 3.7 years (bottom 40% of its family); the 4 officers and directors filing in the last fifteen months have been on the record a median of 10.6 years (top 6%); no officer or director change was reported on Form 8-K since 2023-11-13, against the 4 people in charge now (top 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

TherapeuticsMD, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 19.9% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is 81.2% of revenue (top 2%) (its annual report).

From the record

TherapeuticsMD, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -64.9% a year over the last three filed years against -37.3% over all 7, slowing (bottom 22% of its family); the newest year grew 71.7% (top 18%); research spending grew -36.2% a year (bottom 10%); capital spending grew -46.1% a year (bottom 24%) (its annual reports). TherapeuticsMD, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

TherapeuticsMD, Inc.'s newest year against its own record: revenue of $3 million in fiscal 2025 came in 980.3% above the $280 thousand its prior three years' pace pointed to (top 6% of its family); net income of $569 thousand against a prior three-year average of $33 million (bottom 14%); a net margin of -18.8% against losses larger than its revenue before (top 25%) (its annual reports).